Biotricity, Inc. - Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flow from operating activities:
Net loss	$ (8,623,738)	$ (7,809,291)
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation	1,002,201	626,136
Issuance of shares for services	1,908,481	1,018,210
Issuance of warrants for services, at fair value	370,358	876,438
Accretion expense, including day one derivative loss	879,416	1,177,674
Change in fair value of derivative liabilities	20,588	689,447
Fair value of warrants issued
Changes in operating assets and liabilities:
Harmonized sales tax recoverable	(34,796)	28,614
Deposits and other receivables	3,678	35,909
Accounts payable and accrued liabilities	(400,543)	(392,002)
Net Cash used in operating activities	(4,874,535)	(3,748,865)
Cash flows from financing activities:
Issuance of shares, net	4,860,970	1,237,923
Proceeds from exercise of warrants	428,311	105,500
Issuance of convertible debentures, net		2,455,000
Proceeds from issuance of stock options
Due to shareholders		169,081
Net Cash provided by financing activities	5,289,281	3,967,504
Effect of foreign currency translation	4,029	152,586
Net increase in cash during the year	414,746	218,639
Cash, beginning of year	424,868	53,643
Cash, end of year	843,643	424,868
Supplementary Cash Flow Information
Interest paid
Taxes paid
Conversion of debt to equity on adoption of ASU 2017-11	$ 4,074,312
Conversion of convertible notes into common stock		2,906,999